Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CPRX Catalyst Pharmaceuticals

Market Closed 04-17 16:00:00 EDT

22.52

+0.33

+1.49%

盘后22.52

+0.000.00%

19:53 EDT

High22.67	Low22.14	Vol720.88K
Open22.26	D1 Closing22.19	Amplitude2.39%
Mkt Cap2.74B	Tradable Cap2.56B	Total Shares121.45M
T/O16.20M	T/O Rate0.63%	Tradable Shares113.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceuticals","latestPrice":22.52,"timestamp":1744920000000,"preClose":22.19,"halted":0,"volume":720883,"hourTrading":{"tag":"盘后","latestPrice":22.52,"preClose":22.52,"latestTime":"19:53 EDT","volume":36652,"amount":825405.36,"timestamp":1744934036931},"delay":0,"floatShares":113799966,"shares":121449655,"eps":1.31,"marketStatus":"Market Closed","change":0.33,"latestTime":"04-17 16:00:00 EDT","open":22.26,"high":22.6743,"low":22.1433,"amount":16201173.562043998,"amplitude":0.02393,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.31,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1162962000000,"exchange":"NASDAQ","adjPreClose":22.19,"preHourTrading":{"tag":"盘前","latestPrice":22.12,"preClose":22.19,"latestTime":"09:24 EDT","volume":29,"amount":640.7799689999999,"timestamp":1744896293825},"postHourTrading":{"tag":"盘后","latestPrice":22.52,"preClose":22.52,"latestTime":"19:53 EDT","volume":36652,"amount":825405.36,"timestamp":1744934036931},"volumeRatio":0.6257429294519234,"impliedVol":0.4388,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"2528779062","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2528779062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528779062?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 05:26","pubTimestamp":1744925160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rose 1.49% to $22.52 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 0.13% to 16,286.45 and Dow Jones Industrial Average  falling 1.33% to 39,142.23.Catalyst Pharmaceuticals Inc. closed 13.91% short of its 52-week high of $26.16, which the company reached on March 24th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 2.31% to $157.47, Pfizer Inc.  rose 0.45% to $22.14, and Abbott Laboratories  rose 0.99% to $130.98.Trading volume  remained 633,817 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 17, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswire","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2528718939","title":"Citi Remains a Buy on Catalyst Pharma (CPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718939?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 19:16","pubTimestamp":1744888573,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price targe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-catalyst-pharma-cprx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-catalyst-pharma-cprx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","CPRX","BK4139","IE0034390439.USD"],"gpt_icon":0},{"id":"2528206659","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2528206659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528206659?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 05:25","pubTimestamp":1744838700,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  slipped 4.48% to $22.19 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 3.07% to 16,307.16 and Dow Jones Industrial Average  falling 1.73% to 39,669.39.The stock's fall snapped a three-day winning streak.Catalyst Pharmaceuticals Inc. closed 15.17% short of its 52-week high of $26.16, which the company reached on March 24th.The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson  rose 0.19% to $153.91, Pfizer Inc.  fell 1.78% to $22.04, and Abbott Laboratories  rose 2.76% to $129.70.Trading volume  remained 256,587 below its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 16, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publishe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2527914727","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2527914727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527914727?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 05:24","pubTimestamp":1744665840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  advanced 3.40% to $22.80 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.64% to 16,831.48 and the Dow Jones Industrial Average  rising 0.78% to 40,524.79.This was the stock's second consecutive day of gains.Catalyst Pharmaceuticals Inc. closed 12.84% below its 52-week high of $26.16, which the company reached on March 24th.The stock outperformed some of its competitors Monday, as Johnson & Johnson  rose 1.73% to $154.36, Pfizer Inc.  rose 0.96% to $22.12, and Abbott Laboratories  rose 0.85% to $127.96.Trading volume  remained 311,482 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 14, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2526827642","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2526827642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526827642?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 05:24","pubTimestamp":1744406640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rallied 2.80% to $22.05 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 2.06% to 16,724.46 and the Dow Jones Industrial Average  rising 1.56% to 40,212.71.Catalyst Pharmaceuticals Inc. closed 15.70% short of its 52-week high of $26.16, which the company reached on March 24th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  rose 2.04% to $151.73, Pfizer Inc.  rose 1.48% to $21.91, and Abbott Laboratories  rose 1.91% to $126.88.Trading volume  remained 244,798 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 11, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2526402613","title":"Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526402613","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526402613?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 00:59","pubTimestamp":1744390789,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc.  stands against other best Russell 2000 stocks to buy according to Wall Street analysts.Since President Trump announced new tariffs, the U.S. stock market has been steadily declining. The Wall Street Journal has estimated the loss to be around $6.6 trillion. Many large economies like China and the EU have started retaliating against these new rates, sparking a global trade war and making investors scramble to make sense of the chaos.READ ALSO:10 Best Low-Cost Stocks to Buy According to Billionaires. Is this a buying opportunity or a trap?We have put together our list by following a few criteria. Primarily, all the stocks we have considered for our list are small caps and part of the Russell 2000. We have filtered out those stocks that do not have a strong Buy rating from the analysts. The criteria ensu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catalyst-pharmaceuticals-inc-cprx-best-165949030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034390439.USD",".IXIC","NQmain","SQQQ","USAW.SI","QLD","CPRX","NVIW.SI","IE00B19Z6F94.USD","TSYW.SI","USJW.SI","PSQ","TQQQ","MNQmain","QID","BK4139"],"gpt_icon":1},{"id":"2526105973","title":"Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2526105973","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526105973?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 03:03","pubTimestamp":1744225433,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals saw a minor decline of 3% over the past month amidst a backdrop of broader market volatility triggered by new tariffs and economic uncertainties. Despite the relatively modest price movement for the company compared to the significant 12% market drop, potential concerns related to ongoing tariff discussions in the pharmaceutical sector may have added weight. As broader economic concerns and tariff-related market downturns continue to influence investor sentiment, Catalyst's recent performance appears to mirror the market trend, highlighting the effects of external economic pressures over specific company events in this recent period.Be aware that Catalyst Pharmaceuticals is showing 1 warning sign in our investment analysis.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catalyst-pharmaceuticals-nasdaqcm-cprx-navigates-190353529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z6F94.USD","CPRX","BK4139","IE0034390439.USD"],"gpt_icon":0},{"id":"2526268698","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2526268698","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526268698?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 05:24","pubTimestamp":1744147440,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  shed 1.88% to $21.40 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 2.15% to 15,267.91 and Dow Jones Industrial Average  falling 0.84% to 37,645.59.This was the stock's fourth consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 18.19% short of its 52-week high of $26.16, which the company achieved on March 24th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 0.41% to $150.00, Pfizer Inc.  fell 3.49% to $21.84, and Abbott Laboratories  fell 0.73% to $123.95.Trading volume  eclipsed its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2525902408","title":"BRIEF-Catalyst Pharmaceuticals Announces Health Canada’S Acceptance Of Agamree® New Drug Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2525902408","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525902408?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:31","pubTimestamp":1744119094,"startTime":"0","endTime":"0","summary":"BRIEF-Catalyst Pharmaceuticals Announces Health Canada’S Acceptance Of Agamree New Drug SubmissionApril 8 (Reuters) - Catalyst Pharmaceuticals Inc CPRX.O:CATALYST PHARMACEUTICALS ANNOUNCES HEALTH CANA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX","IE0034390439.USD","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2525891549","title":"Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891549?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:06","pubTimestamp":1744113960,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., April 08, 2025  -- Catalyst Pharmaceuticals, Inc.  , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee inCanada,Kye Pharmaceuticals, Inc. , hasannounced that Health Canada has accepted the New Drug Submission  for AGAMREE, a novel corticosteroid treatment for Duchenne muscular dystrophy , for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed with DMD in Canada.“We are pleased that Health Canada has accepted the New Drug Submission for AGAMREE with a Priority Review, recognizing its potential to address a significant unmet need for patients with Duchenne muscular dystrophy in Canada,” stated Ric","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-health-canada-120600973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034390439.USD","BK4139","CPRX","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2525791270","title":"Catalyst Pharmaceuticals Inc. Stock Slides 5.5%, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2525791270","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525791270?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 04:34","pubTimestamp":1744058040,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc. slid 5.5% to $21.81 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.1% to 15,603.26 and the Dow Jones Industrial Average falling 0.9% to 37,965.60.This was the stock's third consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 16.6% below its 52-week high of $26.16, which the company achieved on March 24th.The stock underperformed when compared to some of its competitors, as Johnson & Johnson fell 1.7% to $150.62, Pfizer Inc. fell 1.5% to $22.63, and Abbott Laboratories rose 0.34% to $124.86.Trading volume totaled 2.4 million, compared to the 50-day average of 1.3 million.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2525753482","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2525753482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525753482?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 05:19","pubTimestamp":1743801540,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  slid 4.31% to $23.07 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 5.82% to 15,587.79 and Dow Jones Industrial Average  falling 5.50% to 38,314.86.This was the stock's second consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 11.81% short of its 52-week high of $26.16, which the company achieved on March 24th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson  fell 4.12% to $153.24, Pfizer Inc.  fell 5.43% to $22.97, and Abbott Laboratories  fell 5.46% to $124.44.Trading volume  eclipsed its 50-day average volume of 1.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 4, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published ind","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2524698444","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2524698444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524698444?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 05:26","pubTimestamp":1743629160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rallied 2.26% to $24.46 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 0.87% to 17,601.05 and the Dow Jones Industrial Average  rising 0.56% to 42,225.32.The stock's rise snapped a six-day losing streak.Catalyst Pharmaceuticals Inc. closed 6.49% short of its 52-week high of $26.16, which the company achieved on March 24th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  rose 1.38% to $155.36, Pfizer Inc.  rose 0.65% to $24.70, and Abbott Laboratories  rose 0.18% to $131.93.Trading volume  remained 231,864 below its 50-day average volume of 1.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 2, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2524959434","title":"What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524959434","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524959434?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:19","pubTimestamp":1743596396,"startTime":"0","endTime":"0","summary":"Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 Growth Index generated a return of 1.7% in the fourth quarter, bringing the yearly returns to 15.2%. The portfolio generated positive returns in the fourth quarter and outperformed the Index. The outperformance was driven by stock selection in Information Technology and underweight position and stock selection in Health Care, while stock selection in Communication Services and Consumer Discretionary detracted. For more information on the fund’s best picks in 2024, please check its top five holdings.Renaissance Investment Management Small Cap Growth Strategy stated the following regarding Catalyst Pharmaceuticals, Inc.  in its Q4 2024 investor letter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-catalyst-pharmaceuticals-cprx-investment-121956877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4142","BK4596","USJW.SI","BK4139","USAW.SI","QLD","BK4585","NVIW.SI","IE0034390439.USD","SQQQ","BK4588","IE00B19Z6F94.USD","PSQ","TSYW.SI","NQmain","BK4595","QID","MNQmain","STRK","BK4023","BK4600","CPRX","CHH","TQQQ","BK4516",".IXIC"],"gpt_icon":1},{"id":"2524312409","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2524312409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524312409?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 05:24","pubTimestamp":1743542640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  shed 1.36% to $23.92 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index  rising 0.87% to 17,449.89 and the Dow Jones Industrial Average  falling 0.03% to 41,989.96.This was the stock's sixth consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 8.56% short of its 52-week high of $26.16, which the company achieved on March 24th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 7.59% to $153.25, Pfizer Inc.  fell 3.16% to $24.54, and Abbott Laboratories  fell 0.72% to $131.69.Trading volume  remained 16,667 below its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 1, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2524908486","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524908486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524908486?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 05:23","pubTimestamp":1743456180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  shed 1.78% to $24.25 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 1.00% to 42,001.76 and the NASDAQ Composite Index  falling 0.14% to 17,299.29.This was the stock's fifth consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 7.29% short of its 52-week high of $26.16, which the company reached on March 24th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  rose 1.30% to $165.84, Pfizer Inc.  rose 0.52% to $25.34, and Abbott Laboratories  rose 1.40% to $132.65.Trading volume  remained 6,257 below its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled March 31, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published indepen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2523685638","title":"Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685638","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685638?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:30","pubTimestamp":1743175842,"startTime":"0","endTime":"0","summary":"It has been about a month since the last earnings report for Catalyst Pharmaceutical . Shares have added about 14.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Catalyst due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.It turns out, estimates revision have trended upward during the past month.The consensus estimate has shifted 10.87% due to these changes.Ionis Pharmaceuticals reported revenues of $227 million in the last reported quarter, representing a year-over-year change of -30.2%. EPS of -$0.66 for the same period compares with -$0.06 a year ago.Ionis Pharmaceuticals is expected to post a loss of $1.07 per share for the current quarter, representing a year-over-year change of -9.2%. Over the last 30 days, the Zacks Consensus Estimate has ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catalyst-cprx-14-7-since-153042094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IONS","CPRX"],"gpt_icon":0},{"id":"2522658868","title":"Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’","url":"https://stock-news.laohu8.com/highlight/detail?id=2522658868","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522658868?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 22:45","pubTimestamp":1743086706,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Discussed These 6 Stocks Recently. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc.  stands against other stocks that Jim Cramer discussed.On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave of artificial intelligence investment, drawing a distinct line between this boom and previous capital expenditure surges. He argued that the AI movement stands apart from other booms driven by the private sector, largely because of the immense wealth backing it from Big Tech leaders. Cramer quipped:. READ ALSO:Jim Cramer Recently Put These 10 Stocks Under SpotlightandJim Cramer Recently Talked About These 5 Subscription Stocks. Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks eve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-catalyst-pharmaceuticals-cprx-144506573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CPRX","NQmain","BK4139","USJW.SI","NVIW.SI","USAW.SI",".IXIC","PSQ","QID","SQQQ","TSYW.SI","IE00B19Z6F94.USD","IE0034390439.USD","MNQmain","QLD","TQQQ"],"gpt_icon":1},{"id":"2522356769","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522356769","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522356769?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:25","pubTimestamp":1743024300,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  slid 2.22% to $25.15 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 2.04% to 17,899.01 and Dow Jones Industrial Average  falling 0.31% to 42,454.79.This was the stock's second consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 3.85% short of its 52-week high of $26.16, which the company reached on March 24th.The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson  rose 0.43% to $161.72, Pfizer Inc.  fell 1.33% to $25.21, and Abbott Laboratories  rose 0.80% to $126.61.Trading volume  eclipsed its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled March 26, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2522090886","title":"With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business","url":"https://stock-news.laohu8.com/highlight/detail?id=2522090886","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522090886?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:04","pubTimestamp":1742925875,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Catalyst Pharmaceuticals' stock price is sensitive to their trading actions. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.To get a sense of who is truly in control of Catalyst Pharmaceuticals, Inc. , it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 81% to be precise, is institutions. Put another way, the group faces the maximum upside potential .And last week, institutional investors ended up benefitting the most after the company hit US$2.9b in market cap. The gains from last week would have further boosted the one-year return to shareholders which currently stand at 62%.Let's take a closer look to see what the different types of shareholders can tell us about Catalyst Pharmaceuticals.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/81-ownership-catalyst-pharmaceuticals-inc-180435671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","IE00BGHQF748.EUR","IE00B64PRP62.GBP","QLD","NQmain","IE0034390439.USD","SQQQ","MNQmain","PSQ","BK4585","BK4588",".IXIC","BK4139","LU2210150020.SGD","IE00B19Z6F94.USD","IE00BKPKM429.USD","TQQQ","BK4112","USAW.SI","USJW.SI","IE00B3QW5Z07.USD","CPRX","LU2095319765.USD","LU2210149790.SGD","NVIW.SI","TSYW.SI","NDAQ"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.0499},{"period":"1month","weight":0.0199},{"period":"3month","weight":-0.0114},{"period":"6month","weight":0.0603},{"period":"1year","weight":0.4075},{"period":"ytd","weight":0.0791}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.055293},{"month":2,"riseRate":0.684211,"avgChangeRate":-0.010782},{"month":3,"riseRate":0.684211,"avgChangeRate":0.101942},{"month":4,"riseRate":0.368421,"avgChangeRate":0.030939},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.032711},{"month":6,"riseRate":0.555556,"avgChangeRate":0.04776},{"month":7,"riseRate":0.611111,"avgChangeRate":0.118672},{"month":8,"riseRate":0.666667,"avgChangeRate":0.234994},{"month":9,"riseRate":0.388889,"avgChangeRate":-0.026925},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.055859},{"month":11,"riseRate":0.555556,"avgChangeRate":0.010506},{"month":12,"riseRate":0.315789,"avgChangeRate":-0.031408}],"exchange":"NASDAQ","name":"Catalyst Pharmaceuticals","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Catalyst Pharmaceuticals,CPRX,Catalyst Pharmaceuticals股票,Catalyst Pharmaceuticals股票老虎,Catalyst Pharmaceuticals股票老虎国际,Catalyst Pharmaceuticals行情,Catalyst Pharmaceuticals股票行情,Catalyst Pharmaceuticals股价,Catalyst Pharmaceuticals股市,Catalyst Pharmaceuticals股票价格,Catalyst Pharmaceuticals股票交易,Catalyst Pharmaceuticals股票购买,Catalyst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction